Vistagen Therapeutics (VTGN) Projected to Post Quarterly Earnings on Tuesday

Vistagen Therapeutics (NASDAQ:VTGN) will likely be announcing its Q4 2025 earnings results before the market opens on Tuesday, June 10th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $0.18 million for the quarter.

Vistagen Therapeutics Trading Down 0.4%

Shares of Vistagen Therapeutics stock opened at $2.36 on Monday. The stock has a market capitalization of $68.11 million, a price-to-earnings ratio of -1.59 and a beta of 0.70. Vistagen Therapeutics has a twelve month low of $1.90 and a twelve month high of $4.21. The business’s 50 day simple moving average is $2.29 and its 200-day simple moving average is $2.60.

Institutional Investors Weigh In On Vistagen Therapeutics

An institutional investor recently bought a new position in Vistagen Therapeutics stock. Cubist Systematic Strategies LLC acquired a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,088 shares of the company’s stock, valued at approximately $25,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.